Abstract
Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
Keywords: Cancer, inflammation, kinase, P-TEFb, inhibitor, therapeutics, angiogenesis, cyclin-dependent kinases (CDKs), anticancer activity, chromosome condensation
Current Pharmaceutical Design
Title:Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Volume: 18 Issue: 20
Author(s): Vladimir Krystof, Sonja Baumli and Robert Furst
Affiliation:
Keywords: Cancer, inflammation, kinase, P-TEFb, inhibitor, therapeutics, angiogenesis, cyclin-dependent kinases (CDKs), anticancer activity, chromosome condensation
Abstract: Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
Export Options
About this article
Cite this article as:
Krystof Vladimir, Baumli Sonja and Furst Robert, Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672750
DOI https://dx.doi.org/10.2174/138161212800672750 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MiR-340 Reduces the Accumulation of Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer’s Disease
Current Neurovascular Research MAP Kinase Pathways in Neuronal Cell Death
CNS & Neurological Disorders - Drug Targets Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Targeting Autophagy in the Brain: A Promising Approach?
Central Nervous System Agents in Medicinal Chemistry MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Docosahexaenoic Acid (DHA) Sensitizes Brain Tumor Cells to Etoposide-Induced Apoptosis
Current Molecular Medicine The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry ER Stress and Autophagy
Current Molecular Medicine Novel Approaches to Study the Involvement of α7-nAChR in Human Diseases
Current Drug Targets Embryonic Morphogenetic Field Induces Phenotypic Reversion in Cancer Cells. Review Article
Current Pharmaceutical Biotechnology Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Current Pharmaceutical Design Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry